Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 59 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $299,126 | -16.5% | 54,887 | +4.0% | 0.00% | – |
| Q2 2023 | $358,437 | +146800.4% | 52,789 | +8.5% | 0.00% | – |
| Q1 2023 | $244 | +2.5% | 48,634 | -0.2% | 0.00% | – |
| Q4 2022 | $238 | -100.0% | 48,749 | +4.2% | 0.00% | -100.0% |
| Q3 2022 | $675,000 | +2.6% | 46,805 | +7.6% | 0.00% | 0.0% |
| Q2 2022 | $658,000 | +53.4% | 43,511 | +20.6% | 0.00% | 0.0% |
| Q1 2022 | $429,000 | -27.3% | 36,092 | -0.9% | 0.00% | 0.0% |
| Q4 2021 | $590,000 | -44.2% | 36,417 | -1.6% | 0.00% | 0.0% |
| Q3 2021 | $1,057,000 | -10.7% | 37,022 | +5.7% | 0.00% | -50.0% |
| Q2 2021 | $1,184,000 | +9.7% | 35,021 | -1.9% | 0.00% | +100.0% |
| Q1 2021 | $1,079,000 | -43.4% | 35,696 | -7.3% | 0.00% | -66.7% |
| Q4 2020 | $1,906,000 | +35.9% | 38,496 | +5.3% | 0.00% | +50.0% |
| Q3 2020 | $1,403,000 | -22.4% | 36,555 | -12.7% | 0.00% | -33.3% |
| Q2 2020 | $1,809,000 | +147.1% | 41,875 | +49.3% | 0.00% | +50.0% |
| Q1 2020 | $732,000 | -14.0% | 28,048 | +3.0% | 0.00% | +100.0% |
| Q4 2019 | $851,000 | +48.0% | 27,222 | +23.4% | 0.00% | 0.0% |
| Q3 2019 | $575,000 | +17.3% | 22,053 | +2.9% | 0.00% | 0.0% |
| Q2 2019 | $490,000 | – | 21,437 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sofinnova Investments, Inc. | 2,104,278 | $54,837,000 | 4.96% |
| Cormorant Asset Management, LP | 883,800 | $23,032,000 | 1.40% |
| SPHERA FUNDS MANAGEMENT LTD. | 190,000 | $4,951,000 | 0.76% |
| Perceptive Advisors | 854,940 | $22,280,000 | 0.60% |
| Artal Group S.A. | 400,000 | $10,424,000 | 0.42% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 207,089 | $5,397,000 | 0.18% |
| Vident Investment Advisory, LLC | 64,571 | $1,683,000 | 0.15% |
| Tuttle Capital Management, LLC | 11,618 | $309,000 | 0.08% |
| Baker Brothers Advisors | 102,800 | $2,679,000 | 0.02% |
| AXA S.A. | 311,010 | $8,104,000 | 0.02% |